GlySens Incorporated, a San Diego, California-based developer of long term continuous glucose monitoring system for people with diabetes, closed a $20M Series D financing.
Backers included existing and new investors.
The company intends to use the funds to further expand its clinical trials to support a CE-Marking application, hire additional staff, and complete the build-out of a new facility and optimized manufacturing plant.
Led by William Markle, President and CEO, and Joseph Lucisano, PhD, co-founder and Chief Technology Officer, GlySens develops an implantable continuous glucose monitoring system (the GlySens ICGM® system) comprised of a fully implanted sensor (designed for long operational life) and an external receiver with monitor to provide provide subjects with diabetes with a means for glucose monitoring and with the information they need including glucose reporting and alerts regarding hypo- and hyperglycemic glucose excursions.
FinSMEs
05/01/2015